These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35965587)

  • 1. A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer.
    Shao Y; Luo Z; Yu Y; He Y; Liu C; Chen Q; Zhu F; Nie B; Liu H
    Front Oncol; 2022; 12():939343. PubMed ID: 35965587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study.
    Nie C; He Y; Lv H; Gao M; Gao X; Chen B; Xu W; Wang J; Liu Y; Zhao J; Chen X
    Front Oncol; 2022; 12():885350. PubMed ID: 35860585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of anlotinib in Chinese patients with metastatic breast cancer: A retrospective observational study.
    Liu S; Zhi W; Zhang L
    J Cell Mol Med; 2024 Mar; 28(5):e18008. PubMed ID: 37891706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer.
    Wang H; Nie C; Xu W; Li J; Gou H; Lv H; Chen B; Wang J; Liu Y; He Y; Zhao J; Chen X
    Therap Adv Gastroenterol; 2024; 17():17562848241245455. PubMed ID: 38617123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer.
    Wang HY; Chu JF; Zhao Y; Tang H; Wang LL; Zhou MQ; Yan Z; Liu YY; Yao ZH
    Cancer Manag Res; 2020; 12():3827-3834. PubMed ID: 32547218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study.
    Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Zhang R; Ruan ZP; Tian T; Liang X; Yao Y
    Cancer Manag Res; 2022; 14():2273-2287. PubMed ID: 35942069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy.
    Yang H; Sun S; Mei Z; Xiang Q; Yang C; Chen M; Xie C; Zhou Y; Qiu H
    Drug Des Devel Ther; 2021; 15():4665-4674. PubMed ID: 34815663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study of anlotinib in patients with persistent, recurrent or metastatic cervical and endometrial cancer.
    Xin L; Ye M; Gao Y; Xiong Q; Hou Q
    Transl Cancer Res; 2024 Jul; 13(7):3718-3728. PubMed ID: 39145063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703).
    Chi Y; Shu Y; Ba Y; Bai Y; Qin B; Wang X; Xiong J; Xu N; Zhang H; Zhou J; Xu J; Cheng Y; Feng J; Hu C; Chen Y; Chen Z; Wang J; Dang C; Wang J; Wan Y; Tang Y; Wang D; Liu J; Wu M; Deng Y; Li X; Li Y; Dong J; Jiang D; Li G; Wu Q; Li J; Qi Y; Sun Y; Cai J
    Oncologist; 2021 Oct; 26(10):e1693-e1703. PubMed ID: 34105207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
    Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
    Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Anlotinib-Containing Regimens in Advanced Non-Small Cell Lung Cancer: A Real-World Study.
    Sun L; Zhao Q; Wang Y; Wang Y; Zheng M; Ding X; Miao L
    Int J Gen Med; 2023; 16():4165-4179. PubMed ID: 37720175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of anlotinib plus anti-programmed cell death 1/ligand 1 (anti-PD-1/PD-L1) antibodies as maintenance therapy after first-line chemotherapy combined with anti-PD-1/PD-L1 antibodies in extensive-stage small cell lung cancer: a real-world study.
    Yang P; Luo H; Zhao L; Xiong F; Tang C
    J Thorac Dis; 2024 Jul; 16(7):4391-4399. PubMed ID: 39144292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of mono-anlotinib mono therapy or in combination with chemotherapy in platinum-resistant recurrent ovarian cancer: a single-center retrospective study.
    Wu Y; Li P; Zhu Y; Zhang F; Su L; Ye Y; Huang Y; Zhang M
    Am J Transl Res; 2023; 15(3):1973-1981. PubMed ID: 37056822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
    Zhong Q; Liu Z
    Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study.
    Yin J; Yin W; Zheng L; Li Y; Luo C; Zhang S; Duan L; Zhou H; Cheng K; Lang J; Xu K
    Clin Med Insights Oncol; 2023; 17():11795549231175714. PubMed ID: 37435019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study.
    Jiang M; Shao B; Wan D; Liu J; He M; Chai Y; Sang D; Wang J; Ma F; Fan Y; Yuan P; Xu B; Li Q
    Ther Adv Med Oncol; 2023; 15():17588359231204856. PubMed ID: 37841751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma.
    Li Q; Su T; Zhang X; Pan Y; Ma S; Zhang L; Zhang X; Gao X
    Cancer Manag Res; 2022; 14():3037-3046. PubMed ID: 36275784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study.
    Zhang S; Wang X; Gu H; Liu JQ
    Cancer Manag Res; 2022; 14():1715-1727. PubMed ID: 35592110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study.
    Nie C; Lv H; Chen B; Xu W; Wang J; Liu Y; Wang S; Zhao J; He Y; Chen X
    Front Oncol; 2022; 12():917353. PubMed ID: 36226061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study.
    Li Y; Sun Z; Sun W; Wang H; Zu J
    Clin Med Insights Oncol; 2022; 16():11795549211067184. PubMed ID: 35095286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.